🚀 Get Ready – The HANDLE NGS Series by AmoyDx is Coming! These solutions are engineered to meet the real-world challenges of modern labs and simplify the complexity of NGS testing. ✨ Stay tuned for the reveal. #PrecisionMedicine #ComingSoon #HANDLEseries #AutomatedReporting

👏 We are proud to announce that the AmoyDx® Pan Lung Cancer PCR Panel has been officially approved by Japan’s Ministry of Health, Labour and Welfare (MHLW) as the primary companion diagnostic (CDx) for IBTROZI® (Taletrectinib adipate). 👉 Full release: amoy-diagnostics-co-ltd.shp.so/l/CyHeyV

✨ AmoyDx will attend #ESMO2025 in Berlin, Germany in October! Our teams will be on site to connect, collaborate, and showcase how we’re breaking barriers to precision oncology. Stop by to Booth 3020 to meet the team and explore opportunities for collaboration.

We're proud to share a new white paper demonstrating the equivalent performance of AmoyDx® NGS panels on GeneMind (GenoLab M & FASTASeq 300) and Illumina NextSeq 550 platforms. Download the full white paper: amoy-diagnostics-co-ltd.shp.so/l/vAtBpl

New data shows AmoyDx® NGS panels perform equally well on Element AVITI System & Illumina NextSeq 550. ✅ High concordance (94–100%) ✅ Strong across sample types ✅ Q30 ≥75% 🔗Delve into the white paper: amoy-diagnostics-co-ltd.shp.so/l/wkAioR #NGS #Genomics #CancerResearch

Our new white paper reveals AmoyDx® NGS panels deliver top performance on Salus sequencers. ✅ 99% SNV/InDel concordance ✅ 100% GSS/HD detection concordance Get the data: amoy-diagnostics-co-ltd.shp.so/l/JaJCBz

The wait is almost over! ESMO Congress 2025 kicks off TOMORROW! Our team is live in Berlin and Booth #3020 is all set to welcome you. Stop by, say hello, and let’s connect – we can’t wait to see you! #ESMO2025 #ESMO #MedicalCongress #Berlin #Oncology

🚀 What a few days at #ESMO2025! Our team has been inspired by insightful conversations, exciting innovations, and meaningful connections. We’re staying until the very last day - visit us at Booth 3020 to explore how we’re breaking barriers in precision oncology.

Thrilled to host our distributor team from Russia at Xiamen HQ for a week of immersive product training! 🧪 From lab ops to bioinformatics, we’re empowering partners to deliver top-notch support and advance precision diagnostics.

🌟We are proud to share that AmoyDx laboratories has once again successfully passed the CAP (College of American Pathologists) proficiency testing programs, reaffirming our commitment to world-class quality and precision.

We are thrilled to present five new studies at the upcoming ESMO Asia 2025! These studies shared by AmoyDx and our collaborators cover a diversity of tumor types and demonstrate how AmoyDx's precision oncology solutions are providing critical insights into cancer with the …

We are excited to pre-announce our upcoming Poster Presentation at #ESMOAsia2025, where we will share the rigorous analytical and clinical validation of the AmoyDx® Super-ARMS ESR1 PCR Kit for liquid biopsy. Stop by the poster session or visit here: amoy-diagnostics-co-ltd.shp.so/l/IYmNCR

Exciting real-world evidence presented at #ESMOAsia2025 demonstrating the performance of the AmoyDx® Essential NGS Panel as a dual tissue and plasma CDx for EGFR Ex20ins NSCLC patients eligible for amivantamab therapy. Explore the full data: amoy-diagnostics-co-ltd.shp.so/l/RjJV2I

🎯 HER2⁺ gastric cancer: new immune biomarkers predict treatment benefit! Tumor + PBMC profiling from ASTRUM Phase II shows responders have active TME & sustained immune activation. Baseline CD22, HHEX, MR1, CD86 linked to benefit. #ESMOAsia2025 #Oncology

🚀 AmoyDx® Pan Lung Cancer PCR Panel has received approval from China's NMPA as a companion diagnostic (CDx) for Tabrecta® (capmatinib), specifically targeting patients with MET exon 14 skipping mutations. 👉Read the full release here: amoy-diagnostics-co-ltd.shp.so/l/GBmwS9 #LungCancer

Happy holidays from the AmoyDx Team! 🎄❄️ This holiday season, we would like to extend our heartfelt thanks to our partners, customers, colleagues and friends around the world. Wishing you and your loved ones peace, joy, good health, and prosperity. ✨

📢 We are thrilled to share that the AmoyDx® PIK3CA Mutation Detection Kit has been approved by the Japanese Ministry of Health, Labour and Welfare (MHLW) as a companion diagnostic for Risovalisib. Read the full press release: amoy-diagnostics-co-ltd.shp.so/l/32DxBt #OvarianCancer #AmoyDx

Today at JSMO 2026 in Japan, AmoyDx was honored to host a dedicated medical seminar, engaging with leading experts on the latest diagnostic trends in NSCLC and the advancement of LC-SCRUM (Asia). A sincere thank you to our distinguished panelists and all who joined us.

Big milestone in #LungCancer care 🎉 AmoyDx, in collaboration with HUTCHMED, has received China’s NMPA approval for our Human c-Met Gene Amplification Detection Kit (FISH) as the companion diagnostic (CDx) for savolitinib. Read the full release: amoy-diagnostics-co-ltd.shp.so/l/7mYMKs

Highlights from #AACR2026 in #NSCLC research: 🔹 LB120: ctDNA MRD monitoring for treatment response & recurrence risk 🔹 3770: DNA methylation model for lymph node metastasis prediction Learn more: LB120: amoy-diagnostics-co-ltd.shp.so/l/eUbeH3 3770: amoy-diagnostics-co-ltd.shp.so/l/XGLVzF